The Value of Treatment (VOT) project is supported through financial contributions from:
Biogen, BMS-Pfizer Alliance, Boehringer Ingelheim GmbH, Grünenthal, Janssen, Livanova, Lundbeck, Medtronic, MSD, Novartis, Pfizer, Roche, Takeda, TEVA Pharmaceuticals, UCB Biopharma, EARLS, EURLSSG, Takeda, Reata, Ipsen, Biomarin, Servier, Roche, EPA and J&J.
All outputs are non-promotional and not specific to any particular treatment or therapy.
For more information on “Value of Treatment 1 & 2”, please contact: Vinciane Quoidbach – Public Health & Policy Research Project Manager (email@example.com)
For more information on “Value of Treatment: Transversal Topics”, please contact: Elke De Witte– EBC Head of Project Development (firstname.lastname@example.org)